AnaptysBio, Inc. is a clinical stage biotechnology company. engages in the
development of antibody product candidates. Its products pipeline include
ANB030, ANB030, and Imsidolimab. It also offers SHM platform that replicate the
natural process of somatic hypermutation embedded within the human immune
system to rapidly develop a diverse range of therapeutic-grade antibodies in
vitro. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J.
Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San
Diego, CA.
